Indefinite Delivery Contract 36E79723D0021

The federal contract IDV award is for the supply of Moxifloxacin HCL Ophthalmic Solution to the Department of Veterans Affairs (VA), Department of Defense (DoD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The contract was awarded to Golden State Medical Supply, Inc., a for-profit pharmaceutical manufacturer and distributor based in Camarillo, California. This is a single-award, indefinite delivery contract with a ceiling value of $3,966,704.10 and a period of performance from June 20, 2023, to June 19, 2024, with four one-year option periods. The contract was not set aside for any specific business category. The original solicitation, issued by the VA National Acquisition Center, sought an uninterrupted source of supply for the contracted item, which will be distributed through the VA's and DoD's respective Pharmaceutical Prime Vendor Programs. The estimated annual requirement is 151,981 bottles of the 3 ML size of Moxifloxacin HCL 0.5% Ophthalmic Solution, and only products rated as an AT1 generic equivalent of Vigamox will be considered.

The parent company of the prime contractor, Gsms Inc., also holds various indefinite delivery contracts with federal agencies, particularly the VA National Acquisition Center and the Defense Logistics Agency, covering a range of pharmaceutical products. However, the specific details of these IDVs, such as the types of goods or services provided, funding agencies involved, or set-aside designations, are not included in the information provided.